Jaya Ganesh

Dr. Jaya Ganesh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
NKNicole Kelly
Nicole Kelly
Joseph OrsiniJoseph Orsini
Joseph Orsini
AGAaron Goldenberg
Aaron Goldenberg
NMNiamh S. Mulrooney
Niamh S. Mulrooney
NBNatalie A. Boychuk
Natalie A. Boychuk
MWMelissa P. Wasserstein
Melissa P. Wasserstein
The increasing availability of novel therapies highlights the importance of screening newborns for rare genetic disorders so that they may benefit from early therapy, when it is most likely to be effective. Pilot newborn screening (NBS) studies are a way to gather objective evidence about the feasibility and utility of screening, the accuracy of screening assays, and the incidence of disease. They are also an optimal way to evaluate the complex ethical, legal and social implications (ELSI) that accompany NBS expansion for disorders. ScreenPlus is a consented pilot NBS program that aims to enroll over 100,000 infants across New York City. The initial ScreenPlus panel includes 14 disorders and uses an analyte-based, multi-tiered screening platform in an effort to enhance screening accuracy. Infants who receive an abnormal result are referred to a ScreenPlus provider for confirmatory testing, management, and therapy as needed, along with longitudinal capture of outcome data. Participation in ScreenPlus requires parental consent, which is obtained in active and passive manners. Patient-facing documents are translated into the ten most common languages spoken at our nine pilot hospitals, all of which serve diverse communities. At the time of consent, parents are invited to receive a series of online surveys to capture their opinions about specific ELSI-related topics, such as NBS policy, residual dried blood spot retention, and the types of disorders that should be on NBS panels. ScreenPlus has developed a stakeholder-based, collective funding model that includes federal support in addition to funding from 14 advocacy and industry sponsors, all of which have a particular interest in NBS for at least one of the ScreenPlus disorders. Taken together, ScreenPlus is a model, multi-sponsored pilot NBS program that will provide critical data about NBS for a broad panel of disorders, while gathering key stakeholder opinions to help guide ethically sensitive decision-making about NBS expansion.

Verified
Journal Article
Open access
PDF file
CDColleen Donnelly
Colleen Donnelly
LELissette Estrella
Lissette Estrella
IGIlona Ginevic
Ilona Ginevic
JGJaya Ganesh
Jaya Ganesh
DNAJC12-deficient hyperphenylalaninemia is a recently described inborn error of metabolism associated with hyperphenylalaninemia, neurotransmitter deficiency, and developmental delay caused by biallelic pathogenic variants of the DNAJC12 gene. The loss of the DNAJC12-encoded chaperone results in the destabilization of the biopterin-dependent aromatic amino acid hydroxylases, resulting in deficiencies in dopamine, norepinephrine, and serotonin. We present the case of a patient who screened positive for hyperphenylalaninemia on newborn screening and was discovered to be homozygous for a likely pathogenic variant of DNAJC12. Here, we review the management of DNAJC12-related hyperphenylalaninemia and compare our patient to other reported cases in the literature to investigate how early detection and management may impact clinical outcomes.

24 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
EKEyal Klang
Eyal Klang
MOMahmud Omar
Mahmud Omar
JGJaya Ganesh
Jaya Ganesh
RAReem Agbareia
Reem Agbareia
PTPrem Timsina
Prem Timsina
GNGirish N Nadkarni
Girish N Nadkarni
We tested state-of-the-art large language models (LLMs) in two configurations for clinical-scale workloads: a single agent handling heterogeneous tasks versus an orchestrated multi-agent system assigning each task to a dedicated worker. Across retrieval, extraction, and dosing calculations, we varied batch sizes from 5 to 80 to simulate clinical traffic. Multi-agent runs maintained high accuracy under load (pooled accuracy 90.6% at 5 tasks, 65.3% at 80) while single-agent accuracy fell sharply (73.1% to 16.6%), with significant differences beyond 10 tasks (FDR-adjusted p < 0.01). Multi-agent execution reduced token usage up to 65-fold and limited latency growth compared with single-agent runs. The design’s isolation of tasks prevented context interference and preserved performance across four diverse LLM checkpoints. This is the first evaluation of LLM agent architectures under sustained, mixed-task clinical workloads, showing that lightweight orchestration can deliver accuracy, efficiency, and auditability at operational scale.

4 April 2025 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
DSDrew B. Sinha
Drew B. Sinha
WSWilliam L. Simpson
William L. Simpson
ATAndrew Ting
Andrew Ting
LBLouise Bier
Louise Bier
MFMary Freeman
Mary Freeman
JGJaya Ganesh
Jaya Ganesh
Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease with multisystem complications including neurodegeneration, hepatosplenomegaly, interstitial lung disease (ILD), bone marrow disease, and growth failure. Non-neurological manifestations of this disease are amenable to enzyme replacement therapy (ERT) with olipudase alfa in both adult and pediatric patients. In this study, we offer evidence for the role of intervention in early childhood pediatric cases. We present longitudinal follow-up for two siblings with ASMD (SMPD1 p.R498L/p.R610del compound heterozygous genotype) who were started on ERT at different ages (ages 3 and 7, duration of treatment >4 years). After initiation of ERT, both siblings demonstrated significant radiographic improvement of interstitial lung disease (ILD), organomegaly, and growth. Notably, the younger sibling who had started earlier on treatment did not experience any deceleration in growth parameters and has normal height and weight for age, while the older sibling showed a decline in growth velocity that improved once treatment was initiated. Similarly, the older sibling showed similar-to-worse ILD and more persistent organomegaly compared to the younger sibling. Treatment has resulted in sustained improvements in both patients. These findings suggest that early intervention with ERT in ASMD may have cumulative benefits for pediatric health and motivate early screening for ASMD in pediatric patients.

14 November 2024 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
WSWilliam L. Simpson
William L. Simpson
JGJaya Ganesh
Jaya Ganesh

23 September 2025 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
JGJaya Ganesh
Jaya Ganesh
CDC. Donnelly
C. Donnelly
ALA. Ligezka
A. Ligezka
GPG. Preston
G. Preston
EME. Morava
E. Morava
TKT. Kozicz
T. Kozicz